| Study Title | Key Findings | Route | Dose | Year |
|---|---|---|---|---|
| Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption | Resulting data led the authors to conclude that cannabis use affects eCB “tone” in ulcerative colitis (UC) patients and may have beneficial effects on disease symptoms in UC patients. | Inhalation, Oral (Ingestion) | UC patients: each cannabis cigarette contained 0.5 g of dried cannabis flowers ( 23% THC and <0.5% CBD), equivalent to 11.5 mg of THC. CD Patients: cannabis oil 8 mg/ml CBD and 2 mg/ml THC. |
2022 |
| Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial | While not significantly affecting anti-inflammatory markers data shows that treatment with a cannabis chemotype I (abundant in THC) produced clinical remission and improved quality of life in patients with mild to moderately active ulcerative colitis. | Inhalation | Patients received either cigarettes containing 0.5 g of dried cannabis flowers with 80mg THC or placebo x 8 weeks. |
2019 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis | Although there was no remission, the physician's overall assessment of illness severity and patients' subjective reports suggest improved quality-of-life outcomes in patients taking CBD-rich botanical extract. | Oral (Ingestion) | CBD (50 to 250 mg in CBD rich botanical extract with a small percentage of THC) |
2019 |
